Patents by Inventor Philip L. Felgner
Philip L. Felgner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160195527Abstract: The present invention provides methods of detecting Borrelia species in a sample (e.g., a sample from a patient suspected of being infected). In particular, the present invention provides compositions and methods for detecting the presence of Borrelia proteins, nucleic acid sequences encoding these proteins, and subject antibodies to these proteins, where the proteins are selected from those listed in Table 3, including: BB0279 (FliL), BBK19, BBK07, BB0286 (FlbB), BBG33, BBL27, BBN34, BBP34, BBQ42, BBQ34, BBM34, BBN27, and BBH13.Type: ApplicationFiled: October 8, 2015Publication date: July 7, 2016Inventors: Alan G. BARBOUR, Philip L. FELGNER
-
Patent number: 9182412Abstract: The present invention provides methods of detecting Borrelia species in a sample (e.g., a sample from a patient suspected of being infected). In particular, the present invention provides compositions and methods for detecting the presence of Borrelia proteins, nucleic acid sequences encoding these proteins, and subject antibodies to these proteins, where the proteins are selected from those listed in Table 3, including: BB0279 (FLiL), BBK19, BBK07, BB0286 (FlbB), BBG33, BBL27, BBN34, BBP34, BBQ42, BBQ34, BBM34, BBN27, and BBH13.Type: GrantFiled: September 20, 2012Date of Patent: November 10, 2015Assignee: The Regents of the University of CaliforniaInventors: Alan G. Barbour, Philip L. Felgner
-
Publication number: 20140348870Abstract: Contemplated compositions and methods employ selected antigens form Plasmodium falciparum and can be used as a vaccine, therapeutic agent, and/or diagnostic tool. Especially preferred antigens are post-challenge immunity associated antigens that are identified via pre-infection suppressive treatment, controlled sub-symptomatic infection to develop immunity, and comparative proteomic differential analysis.Type: ApplicationFiled: November 30, 2012Publication date: November 27, 2014Inventors: Philip L. Felgner, Xiaowu Liang, Robert Sauerwein
-
Publication number: 20130210651Abstract: The present invention provides methods of detecting Borrelia species in a sample (e.g., a sample from a patient suspected of being infected). In particular, the present invention provides compositions and methods for detecting the presence of Borrelia proteins, nucleic acid sequences encoding these proteins, and subject antibodies to these proteins, where the proteins are selected from those listed in Table 3, including: BB0279 (FLiL), BBK19, BBK07, BB0286 (FlbB), BBG33, BBL27, BBN34, BBP34, BBQ42, BBQ34, BBM34, BBN27, and BBH13.Type: ApplicationFiled: September 20, 2012Publication date: August 15, 2013Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Alan G. Barbour, Philip L. Felgner
-
Patent number: 8247181Abstract: Compositions and methods of detecting Borrelia proteins, nucleic acid sequences encoding these proteins, and subject antibodies to these proteins in a sample are disclosed.Type: GrantFiled: September 8, 2008Date of Patent: August 21, 2012Assignee: The Regents of the University of CaliforniaInventors: Alan G. Barbour, Philip L. Felgner
-
Publication number: 20100278866Abstract: Compositions and methods of detecting Borrelia proteins, nucleic acid sequences encoding these proteins, and subject antibodies to these proteins in a sample are disclosed.Type: ApplicationFiled: September 8, 2008Publication date: November 4, 2010Applicant: The Regents of the University of CaliforniaInventors: Alan G. Barbour, Philip L. Felgner
-
Patent number: 7470675Abstract: The present invention provides a pharmaceutical composition, comprising a non-infectious, non-integrating polynucleotide construct comprising a polynucleotide encoding an interferon ? and one or more cationic compounds. The present invention also provides methods of treating cancer in a mammal, comprising administering into a tissue of the mammal a non-infectious, non-integrating polynucleotide construct comprising a polynucleotide encoding a cytokine. In addition, the present invention also relates to the methodology for selective transfection of malignant cells with polynucleotides expressing therapeutic or prophylactic molecules in intra-cavity tumor bearing mammals. More specifically, the present invention provides a methodology for the suppression of an intra-cavity dissemination of malignant cells, such as intraperitoneal dissemination.Type: GrantFiled: February 23, 2007Date of Patent: December 30, 2008Assignee: Vical IncorporatedInventors: Holly Horton, Suezanne Parker, Marston Manthorpe, Philip L. Felgner, Jukka Hartikka
-
Patent number: 7393533Abstract: The invention relates to, among other things, methods of protecting against poxvirus infection or pathogenesis and including pox viruses such as small pox (variola major and variola minor), cowpox, monkey pox vaccinia virus, and Molluscum Contagiosum using compositions such as human, humanized and chimeric antibodies that specifically bind to H3L protein.Type: GrantFiled: November 8, 2005Date of Patent: July 1, 2008Assignee: La Jolla Institute for Allergy and ImmunologyInventors: Shane Crotty, Philip L Felgner, David Huw Davies
-
Patent number: 7319012Abstract: Methods of rapidly generating and analyzing a plurality of polypeptides are disclosed. More specifically, libraries and arrays of polypeptides are assayed in order to determine their individual immunogenic effect. Based on the immunogenic effect of polypeptides, specific subunit vaccines can be developed.Type: GrantFiled: May 29, 2002Date of Patent: January 15, 2008Assignee: Gene Therapy Systems, Inc.Inventors: Philip L. Felgner, Denise L. Doolan
-
Patent number: 7268120Abstract: The present invention provides a pharmaceutical composition, comprising a non-infectious, non-integrating polynucleotide construct comprising a polynucleotide encoding an interferon ? and one or more cationic compounds. The present invention also provides methods of treating cancer in a mammal, comprising administering into a muscle of the mammal a non-infectious, non-integrating DNA polynucleotide construct comprising a polynucleotide encoding a cytokine. In addition, the present invention also relates to the methodology for selective transfection of malignant cells with polynucleotides expressing therapeutic or prophylactic molecules in intra-cavity tumor bearing mammals. More specifically, the present invention provides a methodology for the suppression of an intra-cavity dissemination of malignant cells, such as intraperitoneal dissemination.Type: GrantFiled: April 21, 2000Date of Patent: September 11, 2007Assignee: Vical IncorporatedInventors: Holly Horton, Suezanne Parker, Marston Manthorpe, Philip L. Felgner, Jukka Hartikka
-
Patent number: 7250404Abstract: A method for delivering an isolated polynucleotide to the interior of a cell in a vertebrate, comprising the interstitial introduction of an isolated polynucleotide into a tissue of the vertebrate where the polynucleotide is taken up by the cells of the tissue and exerts a therapeutic effect on the vertebrate. The method can be used to deliver a therapeutic polypeptide to the cells of the vertebrate, to provide an immune response upon in vivo translation of the polynucleotide, to deliver antisense polynucleotides, to deliver receptors to the cells of the vertebrate, or to provide transitory gene therapy.Type: GrantFiled: July 26, 2002Date of Patent: July 31, 2007Assignees: Vical Incorporated, Wisconsin Alumni Research FoundationInventors: Philip L Felgner, Jon A Wolff, Gary H Rhodes, Robert Wallace Malone, Dennis A. Carson
-
Patent number: 6936470Abstract: A method for cloning a nucleic acid fragment into a vector by flanking the fragment with first and second adapter sequences, and contacting the fragment with the vector having sequences homologous to the first and second adapter sequences under conditions such that the nucleic acid fragment is incorporated into the vector by homologous recombination in vivo in a host cell. Additionally, a method for selecting for a successful transformation of a vector by a nucleic acid insert. Also, systems for cloning a nucleic acid fragment into a vector without at least one of a restriction enzyme, a ligase, a gyrase, a single stranded DNA binding protein, or other DNA modifying enzymes. Further, a kit for cloning a nucleic acid fragment into a vector.Type: GrantFiled: April 16, 2002Date of Patent: August 30, 2005Assignee: Gene Therapy Systems, Inc.Inventors: Xiaowu Liang, Andy Teng, Shizhong Chen, Dongyuan Xia, Philip L. Felgner
-
Patent number: 6867195Abstract: A method for delivering an isolated polynucleotide to the interior of a cell in a vertebrate, comprising the interstitial introduction of an isolated polynucleotide into a tissue of the vertebrate where the polynucleotide is taken up by the cells of the tissue and exerts a therapeutic effect on the vertebrate. The method can be used to deliver a therapeutic polypeptide to the cells of the vertebrate, to provide an immune response upon in vivo translation of the polynucleotide, to deliver antisense polynucleotides, to deliver receptors to the cells of the vertebrate, or to provide transitory gene therapy.Type: GrantFiled: June 7, 1995Date of Patent: March 15, 2005Assignee: Vical IncorporatedInventors: Philip L. Felgner, Jon Asher Wolff, Gary H. Rhodes, Robert Wallace Malone, Dennis A. Carson
-
Publication number: 20040132683Abstract: A method for delivering a naked or isolated polynucleotide to the interior of a cell in a vertebrate, comprising the interstitial introduction of a naked polynucleotide into a tissue of the vertebrate where the polynucleotide is taken up by the cells of the tissue and exerts a therapeutic effect on the vertebrate. The method can be used to deliver a therapeutic polypeptide to the cells of the vertebrate, to provide an immune response upon in vivo translation of the polynucleotide, to deliver antisense polynucleotides, to deliver receptors to the cells of the vertebrate, or to provide transitory gene therapy.Type: ApplicationFiled: December 11, 2003Publication date: July 8, 2004Applicant: Vical IncorporatedInventors: Philip L. Felgner, Jon Asher Wolff, Gary H. Rhodes, Robert Wallace Malone, Dennis A. Carson
-
Patent number: 6746868Abstract: Complexes comprising a nucleic acid molecule and a conjugated peptide nucleic acid (PNA). The PNA may be labeled or conjugated to a protein, peptide, carbohydrate moiety or receptor ligand. These complexes are used to transfect cells to monitoring plasmid biodistribution, promote nuclear localization, induce transcriptional activation, lyse the endosomal compartment and facilitate transfection. These complexes increase the efficiency of expression of a particular gene.Type: GrantFiled: November 3, 2000Date of Patent: June 8, 2004Assignee: ISIS Pharmaceuticals, Inc.Inventors: Philip L. Felgner, Olivier Zelphati, C. Frank Bennett
-
Patent number: 6710035Abstract: A method for delivering an isolated polynucleotide to the interior of a cell in a vertebrate, comprising the interstitial introduction of an isolated polynucleotide into a tissue of the vertebrate where the polynucleotide is taken up by the cells of the tissue and exerts a therapeutic effect on the vertebrate. The method can be used to deliver a therapeutic polypeptide to the cells of the vertebrate, to provide an immune response upon in vivo translation of the polynucleotide, to deliver antisense polynucleotides, to deliver receptors to the cells of the vertebrate, or to provide transitory gene therapy.Type: GrantFiled: December 2, 1999Date of Patent: March 23, 2004Assignees: Vical Incorporated, Wisconsin Alumni Research FoundationInventors: Philip L. Felgner, Jon Asher Wolff, Gary H. Rhodes, Robert Wallace Malone, Dennis A. Carson
-
Patent number: 6706694Abstract: The present invention provides a method for delivering a pharmaceutical polypeptide to the interior of a cardiac cell of a vertebrate in vivo, comprising the step of introducing a preparation comprising a pharmaceutically acceptable injectable carrier and naked polynucleotide operatively coding for the polypeptide into the interstitial space of the heart, whereby the naked polynucleotide is taken up into the interior of the cell and has a pharmacological effect on the vertebrate. In a preferred embodiment wherein the polynucleotide encodes polypeptide immunologically foreign to the vertebrate, the delivery method preferably comprises delivering an immunosuppressive agent to the vertebrate to limit immune responses directed to the polypeptide.Type: GrantFiled: June 6, 2000Date of Patent: March 16, 2004Assignees: Vical Incorporated, Wisconsin Alumni Research FoundationInventors: Jon A. Wolff, David J. Duke, Philip L. Felgner
-
Publication number: 20040023911Abstract: A method for delivering a naked or isolated polynucleotide to the interior of a cell in a vertebrate, comprising the interstitial introduction of a naked polynucleotide into a tissue of the vertebrate where the polynucleotide is taken up by the cells of the tissue and exerts a therapeutic effect on the vertebrate. The method can be used to deliver a therapeutic polypeptide to the cells of the vertebrate, to provide an immune response upon in vivo translation of the polynucleotide, to deliver antisense polynucleotides, to deliver receptors to the cells of the vertebrate, or to provide transitory gene therapy.Type: ApplicationFiled: March 14, 2003Publication date: February 5, 2004Applicants: Vical Incorporated, Wisconsin Alumni Research FoundationInventors: Philip L. Felgner, Jon Asher Wolff, Gary H. Rhodes, Robert Wallace Malone, Dennis A. Carson
-
Patent number: 6673776Abstract: A method for delivering an isolated polynucleotide to the interior of a cell in a vertebrate, comprising the interstitial introduction of an isolated polynucleotide into a tissue of the vertebrate where the polynucleotide is taken up by the cells of the tissue and exerts a therapeutic effect on the vertebrate. The method can be used to deliver a therapeutic polypeptide to the cells of the vertebrate, to provide an immune response upon in vivo translation of the polynucleotide, to deliver antisense polynucleotides, to deliver receptors to the cells of the vertebrate, or to provide transitory gene therapy.Type: GrantFiled: June 7, 1995Date of Patent: January 6, 2004Assignees: Vical Incorporated, Wisconsin Alumni Research FoundationInventors: Philip L. Felgner, Jon Asher Wolff, Gary H. Rhodes, Robert Wallace Malone, Dennis A. Carson
-
Publication number: 20030186913Abstract: The present invention provides a method for delivering a pharmaceutical polypeptide to the interior of a cardiac cell of a vertebrate in vivo, comprising the step of introducing a preparation comprising a pharmaceutically acceptable injectable carrier and naked polynucleotide operatively coding for the polypeptide into the interstitial space of the heart, whereby the naked polynucleotide is taken up into the interior of the cell and has a pharmacological effect on the vertebrate. In a preferred embodiment wherein the polynucleotide encodes polypeptide immunologically foreign to the vertebrate, the delivery method preferably comprises delivering an immunosuppressive agent to the vertebrate to limit immune responses directed to the polypeptide.Type: ApplicationFiled: February 10, 2003Publication date: October 2, 2003Applicants: Vical Incorporated, Wisconsin Alumni Research FoundationInventors: Jon A. Wolff, David J. Duke, Philip L. Felgner